Current Oncology Reports

, Volume 13, Issue 5, pp 386-397

First online:

Ongoing Development of Monoclonal Antibodies and Antibody Drug-Conjugates in Lymphoma

  • Eileen M. BoyleAffiliated withDepartment of Hematology, Hôpital Claude Huriez, CHRU
  • , Franck MorschhauserAffiliated withDepartment of Hematology, Hôpital Claude Huriez, CHRUEA 4481 GRIIOT, Université de Lille 2 Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Rituximab, a monoclonal antibody (mAb) directed against CD20, has changed practices in the treatment of patients with B-cell lymphoma. The large success of rituximab has contributed to validate immunotherapy with monoclonal antibodies as a valuable strategy in lymphoma. Recently, better-engineered anti-CD20-mAbs have been designed to improve efficacy and safety. Also, new antibodies targeting other lymphoma subtypes including T-cell lymphoma and Hodgkin’s disease have been developed. Ongoing pharmacology development is concentrating on immuno-drug-conjugates combining the toxicity of chemotherapy, isotopes, or toxins with the specificity of mAbs. This article offers an overview on the development of new antibodies and immuno conjugates in lymphoma.


Lymphoma Monoclonal antibodies Drug-conjugates Radioimmunotherapy